NCT07288216Phase 2Recruiting

Transition to KPL-387 Monotherapy Dosing & Administration Study

Study sponsor: Kiniksa Pharmaceuticals International, plc · KNSA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12-31Estimated
Enrollment · participants120Estimated
Source updated2026-10-28Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Posology: Proportion of participants free from Pericarditis Recurrence by Week 16 Time frame: From first administration of study drug up to Week 16 Measure: Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE. Time frame: Up to 24 Months. After: Measure: Posology: Proportion of participants free from Pericarditis Recurrence by Week 16 Time frame: From baseline up to Week 16 Measure: Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE. Time frame: Up to 24 Months.

Planned enrollment increased by 40 participants

Before: 80 participants (planned). After: 120 participants (planned).

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source